Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States

Fan Di Xia, Bart S. Ferket, Victor Huang, Robert S. Stern, Peggy Wu

Research output: Contribution to journalArticle

Abstract

Background: Treatments for early-stage mycosis fungoides (MF) include topical steroids, topical nitrogen mustard, topical bexarotene, narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and local radiation. The relative cost-effectiveness of each treatment given the differences in treatment failure, disease progression, and therapy escalation is not established. Objective: To compare the cost-effectiveness (CE) of treatment options for stage IA MF. Methods: A state-transition model was constructed with health states of stage IA to stage IV disease, no MF, and death. Treatment-specific remission and relapse rates were obtained from the literature. Lifetime costs were calculated by accounting for medications, office visits, laboratory monitoring, related procedures, work absences, and travel. Results: The order of CE of the study treatments was determined to be as follows: local radiation, $225,399 for 15.40 life-years (LYs); NBUVB, $344,728 for 15.17 LYs; PUVA, $371,741 for 15.07 LYs; topical corticosteroids, $469,354 for 14.65 LYs; topical nitrogen mustard, $951,662 for 14.29 LYs; and topical bexarotene, 11,892,496 for 13.55 LYs. Sensitivity analyses confirmed the CE rankings. Limitations: We assumed a constant probability of response, relapse rates, and 3-month treatment intervals. Conclusions: Local radiation is the most cost-effective treatment for limited local disease, whereas phototherapy (NBUVB or PUVA) is cost-effective for generalized disease. Our findings can serve to inform future studies and recommendations regarding selection of therapy for stage IA MF.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Mycosis Fungoides
Phototherapy
Decision Support Techniques
Health Care Costs
Radiation
Cost-Benefit Analysis
Mechlorethamine
Therapeutics
Ficusin
Costs and Cost Analysis
Office Visits
Recurrence
Treatment Failure
Disease Progression
Adrenal Cortex Hormones
Steroids
Health

Keywords

  • cost-effectiveness
  • mycosis fungoides
  • stage IA
  • treatment

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{a509cffacdd74f88bc969abb0f25a809,
title = "Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States",
abstract = "Background: Treatments for early-stage mycosis fungoides (MF) include topical steroids, topical nitrogen mustard, topical bexarotene, narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and local radiation. The relative cost-effectiveness of each treatment given the differences in treatment failure, disease progression, and therapy escalation is not established. Objective: To compare the cost-effectiveness (CE) of treatment options for stage IA MF. Methods: A state-transition model was constructed with health states of stage IA to stage IV disease, no MF, and death. Treatment-specific remission and relapse rates were obtained from the literature. Lifetime costs were calculated by accounting for medications, office visits, laboratory monitoring, related procedures, work absences, and travel. Results: The order of CE of the study treatments was determined to be as follows: local radiation, $225,399 for 15.40 life-years (LYs); NBUVB, $344,728 for 15.17 LYs; PUVA, $371,741 for 15.07 LYs; topical corticosteroids, $469,354 for 14.65 LYs; topical nitrogen mustard, $951,662 for 14.29 LYs; and topical bexarotene, 11,892,496 for 13.55 LYs. Sensitivity analyses confirmed the CE rankings. Limitations: We assumed a constant probability of response, relapse rates, and 3-month treatment intervals. Conclusions: Local radiation is the most cost-effective treatment for limited local disease, whereas phototherapy (NBUVB or PUVA) is cost-effective for generalized disease. Our findings can serve to inform future studies and recommendations regarding selection of therapy for stage IA MF.",
keywords = "cost-effectiveness, mycosis fungoides, stage IA, treatment",
author = "Xia, {Fan Di} and Ferket, {Bart S.} and Victor Huang and Stern, {Robert S.} and Peggy Wu",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jaad.2018.07.040",
language = "English (US)",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides

T2 - A comparative decision analysis model in the United States

AU - Xia, Fan Di

AU - Ferket, Bart S.

AU - Huang, Victor

AU - Stern, Robert S.

AU - Wu, Peggy

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Treatments for early-stage mycosis fungoides (MF) include topical steroids, topical nitrogen mustard, topical bexarotene, narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and local radiation. The relative cost-effectiveness of each treatment given the differences in treatment failure, disease progression, and therapy escalation is not established. Objective: To compare the cost-effectiveness (CE) of treatment options for stage IA MF. Methods: A state-transition model was constructed with health states of stage IA to stage IV disease, no MF, and death. Treatment-specific remission and relapse rates were obtained from the literature. Lifetime costs were calculated by accounting for medications, office visits, laboratory monitoring, related procedures, work absences, and travel. Results: The order of CE of the study treatments was determined to be as follows: local radiation, $225,399 for 15.40 life-years (LYs); NBUVB, $344,728 for 15.17 LYs; PUVA, $371,741 for 15.07 LYs; topical corticosteroids, $469,354 for 14.65 LYs; topical nitrogen mustard, $951,662 for 14.29 LYs; and topical bexarotene, 11,892,496 for 13.55 LYs. Sensitivity analyses confirmed the CE rankings. Limitations: We assumed a constant probability of response, relapse rates, and 3-month treatment intervals. Conclusions: Local radiation is the most cost-effective treatment for limited local disease, whereas phototherapy (NBUVB or PUVA) is cost-effective for generalized disease. Our findings can serve to inform future studies and recommendations regarding selection of therapy for stage IA MF.

AB - Background: Treatments for early-stage mycosis fungoides (MF) include topical steroids, topical nitrogen mustard, topical bexarotene, narrowband ultraviolet B (NBUVB), psoralen plus ultraviolet A (PUVA), and local radiation. The relative cost-effectiveness of each treatment given the differences in treatment failure, disease progression, and therapy escalation is not established. Objective: To compare the cost-effectiveness (CE) of treatment options for stage IA MF. Methods: A state-transition model was constructed with health states of stage IA to stage IV disease, no MF, and death. Treatment-specific remission and relapse rates were obtained from the literature. Lifetime costs were calculated by accounting for medications, office visits, laboratory monitoring, related procedures, work absences, and travel. Results: The order of CE of the study treatments was determined to be as follows: local radiation, $225,399 for 15.40 life-years (LYs); NBUVB, $344,728 for 15.17 LYs; PUVA, $371,741 for 15.07 LYs; topical corticosteroids, $469,354 for 14.65 LYs; topical nitrogen mustard, $951,662 for 14.29 LYs; and topical bexarotene, 11,892,496 for 13.55 LYs. Sensitivity analyses confirmed the CE rankings. Limitations: We assumed a constant probability of response, relapse rates, and 3-month treatment intervals. Conclusions: Local radiation is the most cost-effective treatment for limited local disease, whereas phototherapy (NBUVB or PUVA) is cost-effective for generalized disease. Our findings can serve to inform future studies and recommendations regarding selection of therapy for stage IA MF.

KW - cost-effectiveness

KW - mycosis fungoides

KW - stage IA

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85053929636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053929636&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.07.040

DO - 10.1016/j.jaad.2018.07.040

M3 - Article

C2 - 30081119

AN - SCOPUS:85053929636

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

ER -